Published in final edited form as:

Hepatology. 2011 July ; 54(1): 173–184. doi:10.1002/hep.24351.

Risk Factors of Cholangiocarcinoma

Gia L. Tyson, MD and Hashem B. El-Serag, MD, MPH

Sections of Gastroenterology and Health Services Research at the Michael E. DeBakey Veterans Affairs Medical Center and Baylor College of Medicine, Houston, TX. Dr. El-Serag is the Chief, Gastroenterology and Hepatology Section at the Michael E. DeBakey Veterans Affairs Medical Center and Baylor College of Medicine

Abstract

Cholangiocarcinoma is the second most common primary hepatic malignancy after hepatocellular cancer. It accounts for approximately 10–25% of all hepatobiliary malignancies. There are considerable geographic and demographic variations in the incidence of cholangiocarcinoma. There are several established risk factors for CC including parasitic infections, primary sclerosing cholangitis, biliary-duct cysts, hepatolithiasis, and toxins. Other less-established, potential risk factors include inflammatory bowel disease, hepatitis C virus, hepatitis B virus, cirrhosis, diabetes, obesity, alcohol drinking, tobacco smoking, and host genetic polymorphisms. In studies where the distinction between ICC and ECC was used, some potential risk factors seem to have differential effect on CC depending on site. Therefore, the consistent use of more refined classification would allow better understanding of risk factors for cholangiocarcinoma.

INTRODUCTION

Cholangiocarcinoma (CC) is a malignant neoplasm of the biliary duct system accounting for 3% of gastrointestinal tumors (1–3). It is the second most common primary hepatic malignancy, representing 10–25% of primary hepatic malignancies worldwide (1, 4, 5). CC rarely occurs before the age of 40; the typical age at presentation is the seventh decade of life (3, 4). Men have a higher incidence of CC than women (3, 6–9) with ratios of 1:1.2–1.5. The incidence of CC varies greatly by geographic region secondary to variations in risk factors (3, 5). The prognosis of CC is poor; therefore, the mortality and incidence rates are similar. Although there are established risk factors for the development of CC, most patients do not have an identifiable risk aside from age (1, 4).

Anatomically CC can be classified as intrahepatic or extrahepatic in location (2). Hilar CC (Klatskin tumors) is typically considered extrahepatic. The distinction between intrahepatic cholangiocarcinoma (ICC) and extrahepatic cholangiocarcinoma (ECC) has become increasingly important, as the epidemiological feature (i.e., incidence and risk factors) associated with each may be different (1, 2). In this review, we will distinguish between ICC and ECC because epidemiological differences may exist between them. Otherwise, CC will be used when studies do not distinguish between ICC and ECC.

Population-based incidence data on CC are sparse. Most cancer registries combine cases of CC with other hepatobiliary malignancies, such as hepatocellular cancer (HCC) and gallbladder cancer (6, 8). Worldwide the incidence of CC varies greatly (3, 8). Regions such as Thailand in Southeast Asia have the highest incidence of CC, as high as 113 per 100,000

in men and 50 per 100,000 in women; while in Western countries such as Australia the incidence is low at 0.2 per 100,000 in men and 0.1 per 100,000 in women (3, 5). Differing exposure to risk factors is thought to account for the varying geographic incidences, with parasitic infections and hepatolithiasis being more prevalent in Asia (3, 5). Several studies published in the early 2000s reported international trends in increased incidence of ICC and decreased incidence of ECC (6, 8), but the role that misclassification of hepatobiliary cancer plays in explaining epidemiological trends may be substantial.

The incidence of CC in the United States is reported from the population-based registries of the Surveillance, Epidemiology, and End Results (SEER) program. The age-adjusted annual incidence of ICC increased from 0.13 per 100,000 persons in 1973 to 0.67 per 100,000 in 1997 (7) and to 0.85 per 100,000 persons in 1995–1999, and a decline in ECC incidence from 1.08 per 100,000 in 1979 to 0.82 per 100,000 in 1998 (3). However, the recent SEER data from 2000–2005 show that the annual incidence of ICC has declined to 0.58 per 100,000 and that of ECC has increased to 0.88 per 100,000.

Differences among studies, registries, and classification of ICC and ECC may account for some of the temporal variations observed in CC (ICC and ECC). For example, Klatskin tumors were not given a unique code in Version 1 of the ICD-O (International Classification of Diseases for Oncology) (1973–1991); therefore, it could have been characterized topographically as ICC or ECC. In Version 2 of the ICD-O (1992–2000), it was given a unique histology code that could be linked to ICC rather than ECC. In Version 3 of the ICD-O (2001–present), the histological code could be linked to either ICC or ECC (10).

In addition to the misclassification of Klatskin tumors, there are other possible reasons for the misclassification of CC include the detection of CCs at an advanced stage which makes it difficult to determine the anatomical origin, and the histological variation of CCs which can result in their classification as other hepatobiliary malignancies. Given that CC is a relatively rare liver cancer in most world regions, misclassifications can substantially impact the findings of epidemiological studies. Consequently, no definitive statement can be made on the temporal trends of CC in most world regions in the absence of striking consistent trends. For example, in the United States, Welzel et al. reported that misclassification of Klatskin tumors had contributed to the temporal trends of increasing ICC and decreasing ECC between 1992 and 2000 (10). Furthermore, recent SEER data (2000–2005) suggest that the temporal trends are reversing with decreased ICC and increased ECC incidence (11).

RISK FACTORS FOR CHOLANGIOCARCINOMA

There are several established risk factors for CC including parasitic infections, primary sclerosing cholangitis, biliary-duct cysts, hepatolithiasis, and toxins. Other less-established, potential risk factors include inflammatory bowel disease (IBD), hepatitis C virus (HCV), hepatitis B virus (HBV), cirrhosis, diabetes, obesity, alcohol, smoking, and host genetic polymorphisms. In studies where the distinction between ICC and ECC was used, some potential risk factors seem to have differential effect on CC depending on site. Therefore, the consistent use of more refined classification would allow better understanding of risk factors for cholangiocarcinoma.

Established Risk factors for Cholangiocarcinoma

Parasitic infections—The hepatobiliary flukes *Opisthorchis viverrini* (*O. viverrini*) and *Clonorchis sinensis* (*C. sinensis*) are associated with the development of CC, particularly in Southeast Asia. They are flat worms that inhabit the bile ducts and, occasionally, the gallbladder and pancreatic duct of mammals. Eggs laid by the adult worms are passed in feces, which may be ingested by snails, where they hatch and then mature into cercariae and

subsequently penetrate the flesh of freshwater fish, where they develop into metacercariae. Infection in humans occurs via ingestion of raw, pickled or undercooked fish (12, 13).

Both parasites increase the susceptibility of cholangiocytes to endogenous and exogenous carcinogens via chronic irritation and increased cellular turnover (12). In 1994 *O. viverrini* was deemed by the International Agency for Research on Cancer as “carcinogenic to humans” secondary to its role in the development of CC. In 2009, the same classification was given to *C. sinensis* (14). Parasitic infections, particularly *O. viverrini* are a major public health issue in Thailand, where the incidence of CC is still increasing in some Northeastern regions and is strongly correlated with the prevalence of parasitic infections (5).

One of the early epidemiological studies (1987–1988) to show a relationship between *O. viverrini* and CC was a hospital-based, case-control study conducted in Thailand by Parkin et al., in which 103 patients with CC were compared with an equal number of age- and sex-matched controls. A strong association was found between elevated *O. viverrini* antibody titers and increased risk of CC (OR 5.0; 95% CI 2.3–11.0) (15). A more recent (1999–2001) population-based, case-control study from Thailand compared 129 cases of CC with an equal number of age- and sex-matched controls. Elevated *O. viverrini* antibody levels were again strongly associated with CC (OR 27.09; CI 6.30–116.57). In endemic areas, the population attributable risk based on this study was as high as 88% (16).

A case-control study by Shin et al. from Korea compared 41 patients with CC with 406 controls and reported a strong association between the presence of *C. sinensis* in the stool and CC (RR 2.7; 95% CI 1.1–6.3) (17). A subsequent 2009 meta-analysis performed by Shin et al. pooled 912 cases and 4,909 controls and confirmed the strong association between *C. sinensis* and CC (OR 4.7; CI 2.2–9.8). In endemic areas, the population attributable risk based on this study was as high as 27.9% for men and 16.2% for women (14).

Biliary-Tract Disorders

Bile-Duct Cysts: Bile (choledochal)-duct cysts are rare congenital disorders characterized by cystic dilatation of the extrahepatic and/or intrahepatic bile ducts. Bile-duct cysts are thought to develop from an abnormal pancreatobiliary junction in which the pancreatic and biliary ducts join outside the duodenum and are typically associated with a long common channel (>10mm) (18). This results in pancreatic enzymes refluxing into the biliary system with subsequent increased intraductal pressure and inflammation, leading to ductal dilatation. With regards to Caroli’s disease, the abnormality is attributed to malformation of the ductal plate (19). It has been postulated that the reflux of pancreatic enzymes, bile stasis, and increased concentration of intraductal bile acids contribute to the formation of malignant cells in patients with bile-duct cysts (20).

Bile-duct cysts are an established risk factor for CC. Type I (solitary, extrahepatic) and IV (extrahepatic and intrahepatic) bile-duct cysts have the higher incidence of CC (20). The lifetime incidence of CC in these patients ranges from 6 to 30% (4, 20). The prevalence of bile-duct cysts is higher in Asian than Western countries (19–23). The incidence of CC is also higher in Asians with bile-duct cysts, at approximately 18%, with the US incidence closer to 6% (19, 21, 23–25). There is an increase in incidence of CC in patients with bile-duct cysts from 0.7% in the first decade of life to > 14% after the age of 20 (26). The average age at malignancy detection has been reported to be 32 years, which is younger than the age at presentation of CC in the general population (20, 24). The risk of malignancy decreases after complete choledochal cyst excision; however, these patients are still at an increased risk of developing CC compared with the general population (19–22, 25).

Patients with bile-duct cysts are reported to have at least 10- to 50-fold increased risk of developing CC (20, 27, 28). In a Korean, hospital-based, case-control study by Lee et al., there was a strong association between choledochal cysts and ICC, with the OR at 10.7 (95% CI 1.8–63.9) (27). In a large, SEER-Medicare study by Welzel et al., there was a strong association between choledochal cysts and increased risk of both ICC and ECC, with an OR of 36.9 (95% CI 22.7–59.7) and 47.1 (95% CI 30.4–73.2), respectively (28).

Primary Sclerosing Cholangitis: Primary sclerosing cholangitis (PSC), an autoimmune disease that results in stricturing of extrahepatic and/or intrahepatic bile ducts, is an established risk factor for CC. Chronic inflammation, proliferation of biliary epithelium, production of endogenous bile mutagens, and bile stasis are postulated mechanisms of carcinogenesis (2). The lifetime incidence of CC among PSC patients ranges from 6 to 36% (29, 30). Although PSC is known to be a strong risk factor for CC, no more than 10% of CC is attributed to PSC (30). Data on the incidence of PSC suggest either no change or a small increase over time. A recent study by Card et al. showed a non-significant rising trend in the incidence of PSC between 1987 and 2002, but the overall incidence estimates in this study were generally lower than most other reports (31). A subsequent study by Lindkvist et al. reported a significantly increased incidence of PSC between 1992 and 2005 (32). Given PSC is the most common known risk factor for CC in the West, trending the incidence of PSC is important for monitoring trends in CC.

A hospital-based, retrospective cohort study by Burak et al. from the Mayo Clinic followed 161 patients with PSC for a median of 11.5 years; 11 patients (6.8%) developed CC with an incidence rate of 0.6% per year. The median time from diagnosis of PSC to diagnosis of CC was 4.1 years (range 0.8–15.0 years), and no association was found between the duration of PSC and the risk of CC (33). Another hospital-based, retrospective cohort study by Claessen et al. followed 211 patients with PSC for a median of 9 years; 7% developed CC. There was no association between duration of PSC and the risk of CC with nearly all the cases of CC presenting within three years of PSC diagnosis (29). It is unclear whether duration of PSC correlates with the risk of developing CC; in fact most cases present relatively soon after PSC diagnosis. Cohort studies suggest that CC develops within the first 1–2 years of PSC diagnosis. A cohort study by Boberg et al. found that 48 of 394 (12.2%) PSC patients developed CC, with 24 of them being diagnosed within 1 year of the diagnosis of PSC (34). In a Swedish cohort study 14 of 125 (11.2%) PSC patients developed CC. Eleven of the 14 (~78%) were diagnosed with CC within 2 years of the diagnosis of PSC (35). Possible explanations for these observations include that early CC may be partly responsible for the patient with PSC seeking medical attention. Given the difficulty of diagnosing early CC in PSC, the initial presentation may result in a diagnosis of the PSC, but the CC is not diagnosed until later.

Smoking and alcohol consumption have also been examined as risk factors for CC in patients with PSC. A case-control study by Chalasani et al. and a cohort study by Burak et al. did not find smoking to be a significant risk factor, while a case-control study by Berquist et al. found a significant association (10 patients vs. 0 patients, $p < 0.0004$) (33, 36, 37). Chalasani et al. also looked at alcohol consumption and reported a significant association between self-reported present or past alcohol consumption and increased risk of CC in patients with PSC (OR 2.95; 95% CI 1.04–8.3) (37). There are no definitive data to suggest smoking and/or alcohol consumption confer an increased risk of CC in PSC patients.

Hepatolithiasis: Hepatolithiasis are calculi or concretions located proximal to the confluence of the right and left hepatic ducts. Hepatolithiasis are found mainly in Southeast Asia (e.g. up to 20% in Taiwan) and are rare in the West (1–2%). It has been postulated that prolonged irritation and inflammation of the biliary epithelium by the calculi, bile stasis, and

bacterial infections predispose to malignancy (38, 39). Additionally, infestation with parasites such as *Clonorchis sinensis* and *Ascaris lumbricoides* has been shown in up to 30% of patients with hepatolithiasis (40).

Hepatolithiasis is an established risk factor for ICC in Asian countries, with 2–10% of patients with hepatolithiasis developing ICC (4, 38, 39). The Korean, hospital-based, case-control study by Lee et al. found a strong association between hepatolithiasis and ICC, with an OR of 50.0 (95% CI 21.2–117.3) (27). A Chinese, hospital-based, case-control study by Zhou et al. also showed a significant association, with the OR at 5.8 (95% CI 1.97–16.9) (41). There is less data on the relationship between hepatolithiasis and ICC in Western countries, but an Italian, hospital-based case-control study also showed a significant association between hepatolithiasis and ICC, with an OR of 6.7 (95% CI 1.3–33.4) (42).

Toxins—The currently banned carcinogenic agent Thorotrast, a radiographic contrast agent used primarily from 1930 to 1960, has been strongly associated with an increased risk of developing CC. The estimated latency period between exposure and malignancy diagnosis ranges between 16 and 45 years; this is because the biological half-life of Thorotrast is 400 years (43). The association between Thorotrast and CC was best shown in a Japanese study that followed 241 patients exposed to Thorotrast during World War II. The study found a more than 300-fold increased risk of CC in exposed patients compared with non-exposed controls (44). Other large studies from Germany and Denmark have also shown a significantly increased risk of CC among patients exposed to Thorotrast (43, 45, 46).

Possible Risk Factors for Cholangiocarcinoma

Inflammatory Bowel Disease (IBD)—Most data describing the association between IBD and CC pertains to patients with IBD and PSC. In the cohort study by Boberg et al. there was a significantly longer duration of IBD in PSC patients with CC than in those without CC (17.4 versus 9.0 years, respectively) (34). Yet the cohort studies by Burak et al. and Claessen et al. did not find a significant association between the presence of IBD and CC in PSC patients (29, 33). In the Swedish cohort study, the cumulative risk of developing CC in PSC patients with IBD for more than 20 years did not differ from that of those with disease duration of less than 20 years (7% versus 8%) (35). The presence and magnitude of association between IBD and CC is likely to be affected by the presence of PSC and by the duration of observation in each study. This is related to the unpredictable onset point for each of PSC and IBD during the course of the other condition. This complexity makes the associations among PSC, IBD and CC difficult to define.

However, there are studies that evaluate IBD, both ulcerative colitis and Crohn's disease, as risk factors independent of PSC for CC (Table 1). Two SEER-Medicare studies showed a positive association of ICC with ulcerative colitis, but not with Crohn's disease (28, 47). One of the studies showed Crohn's disease was significantly associated with ECC (28). A Danish population-based study by Welzel showed that IBD, type not specified, was significantly associated with ICC (48). A different Danish population-based cohort study also found a positive association between UC and CC, but no association with Crohn's. There were no reported differences in those data for ICC versus ECC (49). In these studies PSC was not controlled for in the analysis of IBD; therefore, it remains unclear whether IBD is an independent risk factor for CC. Although IBD may be a risk factor for CC, likely via PSC, it is not clear that IBD confers any added risk for CC in PSC patients.

Cholelithiasis and Cholangitis—Given that proposed mechanisms for CC formation involve chronic inflammation and bile stasis, studies have examined cholelithiasis and cholangitis as risk factors for CC (Table 2). The two large SEER-

Medicare studies showed a strong positive association of CC with choledocholithiasis and cholangitis with risk estimates ranging from 4–64 (28, 47). In the Danish, population-based, case-control study conducted by Welzel et al., choledocholithiasis and cholangitis were again significantly associated with ICC (48). These studies could not definitively exclude PSC-associated cholangitis; therefore, it is unclear if choledocholithiasis and/or cholangitis are independent risk factors for ICC or ECC.

Chronic Viral Hepatitis and Cirrhosis—Hepatitis C virus (HCV), hepatitis B virus (HBV) and liver cirrhosis, regardless of etiology, have been postulated as risk factors for CC (Tables 3,4,5). Tobersenson et al. reviewed the pathology of over 1000 explanted livers and found bile duct dysplasia, a precursor lesion to CC, in approximately 2% of the livers. All affected livers were from patients with underlying cirrhosis caused by HCV, alcohol or both (50). The study supports the biologic plausibility of chronic viral hepatitis and cirrhosis as potential risk factors for CC.

Asian Studies: Several case-control studies, all hospital-based, examined viral hepatitis in relation to CC. A Korean case-control study by Shin et al. that compared 41 cases of CC with 406 non-cancer controls did not find a significant association between HBV or HCV seropositivity and CC (17). In another Korean, case-control study by Lee et al. that compared 622 cases of ICC with 2,488 controls, there was a significant association between ICC and HBV as well as cirrhosis of any etiology. There was no significant association between HCV seropositivity and ICC (27). A case-control study from China by Zhou et al. compared 312 ICC cases with 438 controls and reported a strong association between ICC and HBV seropositivity, but no significant association with HCV seropositivity (41). Lastly, a case-control study from Japan by Yamamoto et al. reported that HCV was a significant risk factor for ICC. The presence of cirrhosis merely trended towards significance, whereas HBV infection was not a significant risk factor for ICC (51).

European Studies: Few Western European studies reported an association between CC and both HCV and cirrhosis. A large, population-based cohort study from Denmark by Sorensen et al. examined cancer risk in 11,605 patients with cirrhosis over a mean follow-up period of 6 years, and reported a 10-fold increased risk of CC among patients with cirrhosis compared with the expected cancer cases in the general population (standardized incidence ratio of 21 versus 2) (52). A hospital-based, case-control study in Italy by Donato et al. compared 26 ICC cases with 824 controls. Both HCV and HBV seropositivity was analyzed, but only HCV was significantly associated with ICC (42).

US Studies: Several US studies have shown an association between the presence of HCV and/or cirrhosis and increased risk of ICC. From The M.D. Anderson Cancer Center, a hospital-based, case-control study by Shaib et al. compared 83 patients with ICC and 163 with ECC to 236 controls. HCV was a significant risk factor for ICC. Cirrhosis was not analyzed as a separate variable, but 80% of HCV-positive patients had cirrhosis. For ECC, neither HCV nor HBV status was a significant risk factor (53). A large, population-based, case-control study by Shaib et al. of Medicare-enrolled patients compared 625 cases of ICC with 90,834 controls. In multivariate analysis, HCV was significantly associated with ICC. It was unclear if patients with HCV also had a recorded diagnostic code for cirrhosis. However, nonspecific cirrhosis was strongly associated with ICC. The prevalence of HBV infection was similar in cases and controls (47). A similar population-based, case-control study by Welzel et al. of Medicare-enrolled patients examined risk factors for both ICC and ECC. There were 549 cases of ECC and 535 cases of ICC compared with 102,782 controls. Significant risk factors for ICC included HCV and nonspecific cirrhosis. Regarding ECC, nonspecific cirrhosis was also a risk factor, but HCV infection was not significant (28). A

large cohort study of US veterans by El-Serag et al. examined the association between HCV and both ICC and ECC in a cohort of 146,394 HCV-infected veterans and 572,293 uninfected controls. The risk for ICC in the HCV-infected cohort, though low at 4 per 100,000 person-years, was more than double that in the controls. The risk of ECC did not differ between the HCV-infected and uninfected veterans (54).

The association of these risk factors with CC is not entirely clear, as studies have differing conclusions; and there is a paucity of population-based or prospective cohort studies. In countries such as Korea and Thailand where both HBV and CC are endemic, data show HBV but not HCV as a risk factor for ICC. On the other hand, countries such as Japan and Western nations, including the United States, where HCV is more prevalent, were more likely to show an association between HCV and ICC (27, 55).

Diabetes and Obesity

Diabetes and obesity have been examined as possible risk factors for CC. Most studies presented in this section were previously discussed in the section on viral hepatitis and cirrhosis (Table 6).

The two SEER-Medicare studies showed a significant positive association between diabetes and CC (28, 47). Another large, population-based, case-control study from the United Kingdom by Grainge et al. found a significant association between diabetes and CC (56). Conversely, a population-based study by Welzel conducted in Denmark did not find a significant association between diabetes and ICC (48). Additionally, one hospital-based case-control study showed a significant association between diabetes and ICC (27), while at least three others failed to show a significant association (Table 6) (41, 51, 53). The data on diabetes as a risk factor for CC, especially ICC, are mostly indicative of a modest association, but is inconsistent.

The data on obesity are limited (Table 6). Obesity was reported as a significant, but weak, risk factor for CC in two population-based, case-control studies. In the study by Grainge et al., a BMI ≥ 30 was significantly associated with CC, type not specified (56). The US study by Welzel et al. reported a significant association between obesity and ICC, but not between obesity and ECC (28). However, in the Danish, population-based study by Welzel et al., there was no significant association between obesity and ICC (48). The data available on obesity are too limited to make any conclusions.

Alcohol Drinking

Several cohort studies, population-based and hospital-based case-control studies have reported a strong association between heavy alcohol use, typically >80 grams/day, and CC (Table 7). A cohort study by Sorensen et al. that examined 11,605 patients with cirrhosis found a significantly increased CC risk in individuals with alcoholic cirrhosis (52). The two SEER-Medicare studies also found alcoholic liver disease to be significantly associated with CC (both ICC and ECC) (28, 47). However, the population-based, case-control study by Grainge et al. did not find alcohol use to be a risk factor for CC (56). Few hospital-based, case-control studies have shown a significant association between alcohol intake and CC (17, 27, 53); while others have not (41, 42, 51). Based on the strong magnitude of association (risk estimate range from 2–15) and studies with different designs, heavy alcohol use is likely to be a risk factor for CC.

Smoking

The data on smoking are not consistent (Table 7). Three large, population-based case-control studies found smoking to be weakly, but significantly, associated with CC, with risk

estimates from 1.38–1.8 (28, 47, 56). For these studies the frequency and/or duration of smoking was not quantified. In several hospital-based case-control studies, there was no significant association between smoking and CC (17, 27, 41, 51, 53). Some of these studies quantified smoking, but there was no consistency among studies in terms of smoking frequency or duration. Smoking may be a weak risk factor for CC; but given the conflicting data, a firm conclusion cannot be made.

Genetic Polymorphisms

Host genetic factors, either alone or interacting with environmental factors, have been examined as possible risk factors for CC. Genes coding for enzymes responsible for metabolism of carcinogens, DNA repair, and inflammation have been examined for polymorphic variants that may be associated with increased susceptibility to CC. In several hospital-based, case-control studies, different gene polymorphisms have been associated with increased as well as decreased risk of developing CC (Table 8) (57–63). Given the varying study populations and lack of study replication in independent cohorts, it is difficult to draw firm conclusions regarding these findings.

The Possible Effect of CC Classification on Risk Factor Epidemiology

A significant limitation to exploring risk factors of CC resides in the classification systems that have been used. 1) Most cancer registries combine CC with other hepatobiliary malignancies; therefore it is unclear if CC also includes HCC and gallbladder cancer (6, 8). 2) When ICC and ECC are reported separately sometimes hepatocellular cancer (HCC) is included with ICC and gallbladder cancer included with ECC (6, 8). 3) Misclassification of Klatskin tumor as ICC has been shown to result in an overestimation of the incidence of ICC and an underestimation of ECC (10). 4) Most CC studies do not distinguish site (e.g., ductal, hilar, peripheral) or histology. Specific risk factors for different types of CC are therefore likely to be missed depending on the distribution of these types in a given study. 5) In studies where the distinction between ICC and ECC was used, some potential risk factors seem to have differential effect on CC depending on site. The consistent use of a more refined classification would allow better understanding of risk factors for cholangiocarcinoma.

Summary

CC is a rare malignancy in Western countries, but more common in Asia. This difference is mostly attributed to the higher prevalence of established risk factors like parasitic infections, bile-duct cysts and hepatolithiasis. However, most cases of CC are not associated with established risk, except in areas endemic for liver flukes. The established risk factors for CC include parasitic infections, biliary-duct cysts, hepatolithiasis, and primary sclerosing cholangitis. Less-established risk factors include IBD, HCV, HBV, cirrhosis, obesity, diabetes, alcohol, smoking, and genetic polymorphisms. There are not enough consistent data to support that IBD independent of PSC, obesity, smoking, or specific genetic polymorphisms confer an increased risk for CC. The available data suggest that diabetes and heavy alcohol drinking may confer an increased risk for CC. The data also suggest that in Western countries HCV is consistently associated with ICC and not ECC. In Asian countries it appears that HBV may be associated with ICC. Cirrhosis is the most consistently illustrated risk factor for ICC, but not ECC. The lack of an accurate and consistent CC classification system may have hindered the conduct and interpretation of risk factors in epidemiological studies.

Acknowledgments

Funding: This work is partly funded by NIH grant T32 DK083266-01A1, and partly by Houston VA HSR&D Center of Excellence (HFP90-020)

Reference List

1. Gatto M, Bragazzi MC, Semeraro R, Napoli C, Gentile R, Torrice A, et al. Cholangiocarcinoma: update and future perspectives. *Dig Liver Dis.* 2010 Apr; 42(4):253–260. [PubMed: 20097142]
2. Patel T. Cholangiocarcinoma. *Nat Clin Pract Gastroenterol Hepatol.* 2006 Jan; 3(1):33–42. [PubMed: 16397610]
3. Shaib Y, El-Serag HB. The epidemiology of cholangiocarcinoma. *Semin Liver Dis.* 2004 May; 24(2):115–125. [PubMed: 15192785]
4. Blechacz BR, Gores GJ. Cholangiocarcinoma. *Clin Liver Dis.* 2008 Feb; 12(1):131–50. ix. [PubMed: 18242501]
5. Sripa B, Pairojkul C. Cholangiocarcinoma: lessons from Thailand. *Curr Opin Gastroenterol.* 2008 May; 24(3):349–356. [PubMed: 18408464]
6. Khan SA, Toledano MB, Taylor-Robinson SD. Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma. *HPB (Oxford).* 2008; 10(2):77–82. [PubMed: 18773060]
7. Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. *Hepatology.* 2001 Jun; 33(6):1353–1357. [PubMed: 11391522]
8. Patel T. Worldwide trends in mortality from biliary tract malignancies. *BMC Cancer.* 2002 May 3; 2(10):10. [PubMed: 11991810]
9. Taylor-Robinson SD, Toledano MB, Arora S, Keegan TJ, Hargreaves S, Beck A, et al. Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968–1998. *Gut.* 2001 Jun; 48(6):816–820. [PubMed: 11358902]
10. Welzel TM, McGlynn KA, Hsing AW, O'Brien TR, Pfeiffer RM. Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States. *J Natl Cancer Inst.* 2006 Jun 21; 98(12):873–875. [PubMed: 16788161]
11. Surveillance, Epidemiology, and End Results (SEER) Program. Research Data (1973–2007). National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch; 2011. www.seer.cancer.gov released April 2010, based on the November 2009 submission
12. Kaewpitoon N, Kaewpitoon SJ, Pengsaa P, Sripa B. *Opisthorchis viverrini*: the carcinogenic human liver fluke. *World J Gastroenterol.* 2008 Feb 7; 14(5):666–674. [PubMed: 18205254]
13. Upatham ES, Viyanant V. *Opisthorchis viverrini* and opisthorchiasis: a historical review and future perspective. *Acta Trop.* 2003 Nov; 88(3):171–176. [PubMed: 14611871]
14. Shin HR, Oh JK, Lim MK, Shin A, Kong HJ, Jung KW, et al. Descriptive epidemiology of cholangiocarcinoma and clonorchiasis in Korea. *J Korean Med Sci.* 2010 Jul; 25(7):1011–1016. [PubMed: 20592891]
15. Parkin DM, Srivatanakul P, Khlat M, Chenvidhya D, Chotiwan P, Insiripong S, et al. Liver cancer in Thailand. I. A case-control study of cholangiocarcinoma. *Int J Cancer.* 1991 May 30; 48(3):323–328. [PubMed: 1645697]
16. Honjo S, Srivatanakul P, Sriplung H, Kikukawa H, Hanai S, Uchida K, et al. Genetic and environmental determinants of risk for cholangiocarcinoma via *Opisthorchis viverrini* in a densely infested area in Nakhon Phanom, northeast Thailand. *Int J Cancer.* 2005 Dec 10; 117(5):854–860. [PubMed: 15957169]
17. Shin HR, Lee CU, Park HJ, Seol SY, Chung JM, Choi HC, et al. Hepatitis B and C virus, *Clonorchis sinensis* for the risk of liver cancer: a case-control study in Pusan, Korea. *Int J Epidemiol.* 1996 Oct; 25(5):933–940. [PubMed: 8921477]
18. Kamisawa T, Egawa N, Nakajima H, Tsuruta K, Okamoto A, Matsukawa M. Origin of the long common channel based on pancreatographic findings in pancreaticobiliary maljunction. *Dig Liver Dis.* 2005 May; 37(5):363–367. [PubMed: 15843087]

19. Mabrut JY, Bozio G, Hubert C, Gigot JF. Management of congenital bile duct cysts. *Dig Surg*. 2010; 27(1):12–18. [PubMed: 20357446]
20. Soreide K, Korner H, Havnen J, Soreide JA. Bile duct cysts in adults. *Br J Surg*. 2004 Dec; 91(12): 1538–1548. [PubMed: 15549778]
21. Edil BH, Cameron JL, Reddy S, Lum Y, Lipsett PA, Nathan H, et al. Choledochal cyst disease in children and adults: a 30-year single-institution experience. *J Am Coll Surg*. 2008 May; 206(5): 1000–1005. [PubMed: 18471743]
22. Kobayashi S, Asano T, Yamasaki M, Kenmochi T, Nakagohri T, Ochiai T. Risk of bile duct carcinogenesis after excision of extrahepatic bile ducts in pancreaticobiliary maljunction. *Surgery*. 1999 Nov; 126(5):939–944. [PubMed: 10568195]
23. Yamaguchi M. Congenital choledochal cyst. Analysis of 1,433 patients in the Japanese literature. *Am J Surg*. 1980 Nov; 140(5):653–657. [PubMed: 6776832]
24. Todani T, Watanabe Y, Toki A, Urushihara N. Carcinoma related to choledochal cysts with internal drainage operations. *Surg Gynecol Obstet*. 1987 Jan; 164(1):61–64. [PubMed: 3026058]
25. Watanabe Y, Toki A, Todani T. Bile duct cancer developed after cyst excision for choledochal cyst. *J Hepatobiliary Pancreat Surg*. 1999; 6(3):207–212. [PubMed: 10526053]
26. Voyles CR, Smadja C, Shands WC, Blumgart LH. Carcinoma in choledochal cysts. Age-related incidence. *Arch Surg*. 1983 Aug; 118(8):986–988. [PubMed: 6870530]
27. Lee TY, Lee SS, Jung SW, Jeon SH, Yun SC, Oh HC, et al. Hepatitis B virus infection and intrahepatic cholangiocarcinoma in Korea: a case-control study. *Am J Gastroenterol*. 2008 Jul; 103(7):1716–1720. [PubMed: 18557716]
28. Welzel TM, Graubard BI, El-Serag HB, Shaib YH, Hsing AW, Davila JA, et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. *Clin Gastroenterol Hepatol*. 2007 Oct; 5(10):1221–1228. [PubMed: 17689296]
29. Claessen MM, Vleggaar FP, Tytgat KM, Siersema PD, van Buuren HR. High lifetime risk of cancer in primary sclerosing cholangitis. *J Hepatol*. 2009 Jan; 50(1):158–164. [PubMed: 19012991]
30. LaRusso NF, Shneider BL, Black D, Gores GJ, James SP, Doo E, et al. Primary sclerosing cholangitis: summary of a workshop. *Hepatology*. 2006 Sep; 44(3):746–764. [PubMed: 16941705]
31. Card TR, Solaymani-Dodaran M, West J. Incidence and mortality of primary sclerosing cholangitis in the UK: a population-based cohort study. *J Hepatol*. 2008 Jun; 48(6):939–944. [PubMed: 18433916]
32. Lindkvist B, Benitod V, Gullberg B, Bjornsson E. Incidence and prevalence of primary sclerosing cholangitis in a defined adult population in Sweden. *Hepatology*. 2010 Aug; 52(2):571–577. [PubMed: 20683956]
33. Burak K, Angulo P, Pasha TM, Egan K, Petz J, Lindor KD. Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. *Am J Gastroenterol*. 2004 Mar; 99(3):523–526. [PubMed: 15056096]
34. Boberg KM, Bergquist A, Mitchell S, Pares A, Rosina F, Broome U, et al. Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation. *Scand J Gastroenterol*. 2002 Oct; 37(10):1205–1211. [PubMed: 12408527]
35. Kornfeld D, Ekbom A, Ihre T. Survival and risk of cholangiocarcinoma in patients with primary sclerosing cholangitis. A population-based study. *Scand J Gastroenterol*. 1997 Oct; 32(10):1042–1045. [PubMed: 9361178]
36. Bergquist A, Glaumann H, Persson B, Broome U. Risk factors and clinical presentation of hepatobiliary carcinoma in patients with primary sclerosing cholangitis: a case-control study. *Hepatology*. 1998 Feb; 27(2):311–316. [PubMed: 9462625]
37. Chalasani N, Baluyut A, Ismail A, Zaman A, Sood G, Ghalib R, et al. Cholangiocarcinoma in patients with primary sclerosing cholangitis: a multicenter case-control study. *Hepatology*. 2000 Jan; 31(1):7–11. [PubMed: 10613720]
38. Kubo S, Kinoshita H, Hirohashi K, Hamba H. Hepatolithiasis associated with cholangiocarcinoma. *World J Surg*. 1995 Jul; 19(4):637–641. [PubMed: 7676713]

39. Lesurtel M, Regimbeau JM, Farges O, Colombat M, Sauvanet A, Belghiti J. Intrahepatic cholangiocarcinoma and hepatolithiasis: an unusual association in Western countries. *Eur J Gastroenterol Hepatol*. 2002 Sep; 14(9):1025–1027. [PubMed: 12352225]
40. Huang MH, Chen CH, Yen CM, Yang JC, Yang CC, Yeh YH, et al. Relation of hepatolithiasis to helminthic infestation. *J Gastroenterol Hepatol*. 2005 Jan; 20(1):141–146. [PubMed: 15610459]
41. Zhou YM, Yin ZF, Yang JM, Li B, Shao WY, Xu F, et al. Risk factors for intrahepatic cholangiocarcinoma: a case-control study in China. *World J Gastroenterol*. 2008 Jan 28; 14(4): 632–635. [PubMed: 18203300]
42. Donato F, Gelatti U, Tagger A, Favret M, Ribero ML, Callea F, et al. Intrahepatic cholangiocarcinoma and hepatitis C and B virus infection, alcohol intake, and hepatolithiasis: a case-control study in Italy. *Cancer Causes Control*. 2001 Dec; 12(10):959–964. [PubMed: 11808716]
43. Lipshutz GS, Brennan TV, Warren RS. Thorotrast-induced liver neoplasia: a collective review. *J Am Coll Surg*. 2002 Nov; 195(5):713–718. [PubMed: 12437262]
44. Kato I, Kido C. Increased risk of death in thorotrast-exposed patients during the late follow-up period. *Jpn J Cancer Res*. 1987 Nov; 78(11):1187–1192. [PubMed: 2826375]
45. Andersson M, Vyberg M, Visfeldt J, Carstensen B, Storm HH. Primary liver tumors among Danish patients exposed to Thorotrast. *Radiat Res*. 1994 Feb; 137(2):262–273. [PubMed: 8134550]
46. van KG, Wesch H, Luhrs H, Liebermann D, Kaul A. Neoplastic diseases induced by chronic alpha-irradiation--epidemiological, biophysical and clinical results of the German Thorotrast Study. *J Radiat Res (Tokyo)*. 1991 Dec; 32(Suppl 2):20–33.
47. Shaib YH, El-Serag HB, Davila JA, Morgan R, McGlynn KA. Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. *Gastroenterology*. 2005 Mar; 128(3):620–626. [PubMed: 15765398]
48. Welzel TM, Mellekjaer L, Gloria G, Sakoda LC, Hsing AW, El GL, et al. Risk factors for intrahepatic cholangiocarcinoma in a low-risk population: a nationwide case-control study. *Int J Cancer*. 2007 Feb 1; 120(3):638–641. [PubMed: 17109384]
49. Erichsen R, Jepsen P, Vilstrup H, Ekbom A, Sorensen HT. Incidence and prognosis of cholangiocarcinoma in Danish patients with and without inflammatory bowel disease: a national cohort study, 1978–2003. *Eur J Epidemiol*. 2009; 24(9):513–520. [PubMed: 19557525]
50. Torbenson M, Yeh MM, Abraham SC. Bile duct dysplasia in the setting of chronic hepatitis C and alcohol cirrhosis. *Am J Surg Pathol*. 2007 Sep; 31(9):1410–1413. [PubMed: 17721197]
51. Yamamoto S, Kubo S, Hai S, Uenishi T, Yamamoto T, Shuto T, et al. Hepatitis C virus infection as a likely etiology of intrahepatic cholangiocarcinoma. *Cancer Sci*. 2004 Jul; 95(7):592–595. [PubMed: 15245596]
52. Sorensen HT, Friis S, Olsen JH, Thulstrup AM, Mellekjaer L, Linet M, et al. Risk of liver and other types of cancer in patients with cirrhosis: a nationwide cohort study in Denmark. *Hepatology*. 1998 Oct; 28(4):921–925. [PubMed: 9755226]
53. Shaib YH, El-Serag HB, Nooka AK, Thomas M, Brown TD, Patt YZ, et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a hospital-based case-control study. *Am J Gastroenterol*. 2007 May; 102(5):1016–1021. [PubMed: 17324130]
54. El-Serag HB, Engels EA, Landgren O, Chiao E, Henderson L, Amaratunge HC, et al. Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: A population-based study of U.S. veterans. *Hepatology*. 2009 Jan; 49(1):116–123. [PubMed: 19085911]
55. Songsivilai S, Dharakul T, Kanistanon D. Hepatitis C virus genotypes in patients with hepatocellular carcinoma and cholangiocarcinoma in Thailand. *Trans R Soc Trop Med Hyg*. 1996 Sep; 90(5):505–507. [PubMed: 8944256]
56. Grainge MJ, West J, Solaymani-Dodaran M, Aithal GP, Card TR. The antecedents of biliary cancer: a primary care case-control study in the United Kingdom. *Br J Cancer*. 2009 Jan 13; 100(1):178–180. [PubMed: 19018260]
57. Hoblinger A, Grunhage F, Sauerbruch T, Lammert F. Association of the c.3972C>T variant of the multidrug resistance-associated protein 2 Gene (MRP2/ABCC2) with susceptibility to bile duct cancer. *Digestion*. 2009; 80(1):36–39. [PubMed: 19451719]

58. Huang WY, Gao YT, Rashid A, Sakoda LC, Deng J, Shen MC, et al. Selected base excision repair gene polymorphisms and susceptibility to biliary tract cancer and biliary stones: a population-based case-control study in China. *Carcinogenesis*. 2008 Jan; 29(1):100–105. [PubMed: 17984110]
59. Ko KH, Kim NK, Yim DJ, Hong SP, Park PW, Rim KS, et al. Polymorphisms of 5,10-methylenetetrahydrofolate reductase (MTHFR C677T) and thymidylate synthase enhancer region (TSER) as a risk factor of cholangiocarcinoma in a Korean population. *Anticancer Res*. 2006 Nov; 26(6B):4229–4233. [PubMed: 17201138]
60. Marahatta SB, Punyarit P, Bhudisawasdi V, Paupairoj A, Wongkham S, Petmitr S. Polymorphism of glutathione S-transferase omega gene and risk of cancer. *Cancer Lett*. 2006 May 18; 236(2): 276–281. [PubMed: 15992993]
61. Melum E, Karlsen TH, Schrumpf E, Bergquist A, Thorsby E, Boberg KM, et al. Cholangiocarcinoma in primary sclerosing cholangitis is associated with NKG2D polymorphisms. *Hepatology*. 2008 Jan; 47(1):90–96. [PubMed: 18023027]
62. Prawan A, Kukongviriyapan V, Tassaneeyakul W, Pairojkul C, Bhudhisawasdi V. Association between genetic polymorphisms of CYP1A2, arylamine N-acetyltransferase 1 and 2 and susceptibility to cholangiocarcinoma. *Eur J Cancer Prev*. 2005 Jun; 14(3):245–250. [PubMed: 15901993]
63. Sakoda LC, Gao YT, Chen BE, Chen J, Rosenberg PS, Rashid A, et al. Prostaglandin-endoperoxide synthase 2 (PTGS2) gene polymorphisms and risk of biliary tract cancer and gallstones: a population-based study in Shanghai, China. *Carcinogenesis*. 2006 Jun; 27(6):1251–1256. [PubMed: 16361272]

Table 1

IBD as a Potential Risk factor for Cholangiocarcinoma

First author	Country	Study dates	Study design	Risk factor	CC Type	Cases (% with risk factor)	Controls (% with risk factor)	Risk estimate (95% CI)	Selected adjusted variables
Welzel ⁴⁸	Denmark	1978–1991	Case-Control	IBD	ICC	764 (0.92%)	3,056 (0.20%)	4.67 (1.6–13.9)	Age, sex
Erichsen ⁴⁹	Denmark	1978–2003	Cohort	UC	ECC/ICC	Incidence rate 8.2	Incidence rate 2.0	4.1 (2.4–6.8)	Age, sex
				Crohn's	ECC/ICC	Incidence rate 4.3	Incidence rate 1.4	3.0 (0.9–8.6)	
Shalh ⁴⁷	US	1993–1999	Case-control	UC	ICC	625	90,834	2.2 (1.2–3.9)	Age, sex, race, geographic location
				Crohn's	ICC			2.0 (0.6–6.3)	
Welzel ²⁸	US	1993–1999	Case-Control	UC	ICC	535 (2.4%)	102,782 (0.6%)	4.5 (2.6–7.9)	Age, sex, race, geographic location
				Crohn's	ICC	535 (0.9%)	102,782 (0.4%)	2.4 (1.0–5.9)	
				UC	ECC	549 (0.9%)	102,782 (0.6%)	1.7 (0.7–4.0)	
				Crohn's	ECC	549 (1.1%)	102,782 (0.4%)	2.8 (1.3–6.4)	

IBD = inflammatory bowel disease; UC = ulcerative colitis; CC = cholangiocarcinoma; ICC = intrahepatic cholangiocarcinoma; ECC = extrahepatic cholangiocarcinoma; CI = confidence interval

Table 2
Cholangitis and Choledocholithiasis as Potential Risk factors for Cholangiocarcinoma

First author	Country	Study dates	Study design	Risk factor	CC type	Cases (% with risk factor)	Controls (% with risk factor)	Risk estimate (95% CI)	Selected adjusted variables
Welzel ⁴⁸	Denmark	1978–1991	Case-Control	Cholangitis	ICC	764 (1.3%)	3,056 (0.23%)	6.32 (2.3–17.5)	Age, sex
				Choledocholithiasis	ICC	764 (0.79%)	3,056 (0.03%)	23.97 (2.9–198.9)	
Shaib ⁴⁷	US	1993–1999	Case-control	Cholangitis	ICC	625 (3.4%)	90,834 (0.2%)	8.8 (4.9–16.0)	Age, sex, race, geographic location
				Choledocholithiasis	ICC	625 (1.1%)	90,834 (0.3%)	4.0 (1.9–8.5)	
Welzel ²⁸	US	1993–1999	Case-Control	Cholangitis	ICC	535 (12.5%)	102,782 (0.2%)	64.2 (47.7–86.5)	Age, sex, race, geographic location
				Choledocholithiasis	ICC	535 (11%)	102,782 (0.5%)	22.5 (16.9–30.0)	
				Cholangitis	ECC	549 (9.1%)	102,782 (0.2%)	45.7 (32.9–63.6)	
				Choledocholithiasis	ECC	549 (15.8%)	102,782 (0.5%)	34.0 (26.6–43.6)	

CC = cholangiocarcinoma; ICC = intrahepatic cholangiocarcinoma; ECC = extrahepatic cholangiocarcinoma; CI = confidence interval

Table 3

Hepatitis B virus as a Potential Risk factor for Cholangiocarcinoma

First author	Country	Study date	Risk factor	CC Type	Cases (% with risk factor)	Controls (% with risk factor)	Risk estimate (95% CI)	Selected adjusted variables
Shin ¹⁷	Korea	1990–1993	HBsAg+	NS	41 (12.5%)	406 (3.5%)	1.3 (0.3–5.3)	Age, sex, socioeconomic status
Yamamoto ⁵¹	Japan	1991–2002	HBsAg+	ICC	50 (4%)	205 (2%)	Not calculated	Age, sex
Shaib ⁵³	US	1992–2002	HBsAg–/Anti-HBc+	ICC	83 (9.6%)	236 (0%)	28.6 (3.9–1268.1)	Age, sex, race
			HBsAg–/Anti-HBc+	ECC	163 (0%)	236 (0%)	3.2 (0.6–382)	
Shaib ⁴⁷	US	1993–1999	^ HBV	ICC	625 (0.2%)	90,834 (0.2%)	0.8 (0.1–5.9)	Age, sex, race, geographic location
Donato ⁴²	Italy	1995–2000	HBsAg+	ICC	26 (11.5%)	824 (5.5%)	2.7 (0.4–18.5)	Age, sex, residence
Lee ²⁷	Korea	2000–2004	HBsAg+	ICC	622 (13.5%)	2,488 (5.0%)	2.3 (1.6–3.3)	Age, sex
Zhou ⁴¹	China	2004–2006	HBsAg+	ICC	312 (48.4%)	438 (9.6%)	8.9 (5.97–13.2)	Age, sex, date of admission

^ Diagnostic code; HBsAg= Hepatitis B surface antigen; HBc= Hepatitis B core; HBV=Hepatitis B virus; CC = cholangiocarcinoma; NS= Not specified; ICC = intrahepatic cholangiocarcinoma; ECC = extrahepatic cholangiocarcinoma; CI = confidence interval

Table 4

Hepatitis C virus as a Potential Risk factor for Cholangiocarcinoma

First author	Country	Study dates	Study design	Risk factor	CC Type	Cases (% with risk factor)	Controls (% with risk factor)	Risk estimate (95% CI)	Selected adjusted variables
El-Serag ⁵⁴	US	1988–2004	Cohort	^ HCV	ICC	4/100,000 person-years	1.6/100,000 person-years	2.55 (1.3–4.9)	Age, sex
				^ HCV	ECC	4.3/100,000 person-years	4.2/100,000 person-years	1.05 (0.6–1.9)	
Shin ¹⁷	Korea	1990–1993	Case-control	Anti-HCV+	NS	41 (13.8%)	406 (2.3%)	3.9 (0.9–17.1)	Age, sex, SES
Yamamoto ⁵¹	Japan	1991–2002	Case-control	Anti-HCV +	ICC	50 (36%)	205 (3%)	6.02 (1.5–24.1)	Age, sex
Shaib ⁵³	US	1992–2002	Case-control	Anti-HCV+	ICC	83 (6%)	236 (0.8%)	7.9 (1.3–84.5)	Age, sex, race
				Anti-HCV+	ECC	163 (3.7%)	236 (0.8%)	2.8 (0.3–35.1)	
Shaib ⁴⁷	US	1993–1999	Case-control	^ HCV	ICC	625 (0.8%)	90,834 (0.2%)	5.2 (2.1–12.8)	Age, sex, race, geographic location
Welzel ²⁸	US	1993–1999	Case-Control	^ HCV	ICC	535 (<0.9%)	102,782 (0.1%)	4.4 (1.4–14.0)	Age, sex, race, geographic location
				^ HCV	ECC	549 (<0.9%)	102,782 (0.1%)	1.5 (0.2–11.0)	
Donato ⁴²	Italy	1995–2000	Case-control	Anti-HCV +	ICC	26 (23%)	824 (6%)	9.7 (1.6–58.9)	Age, sex, residence
Lee ²⁷	Korea	2000–2004	Case-control	Anti-HCV +	ICC	622 (1.9%)	2,488 (1.9%)	Not calculated	Age, sex
Zhou ⁴¹	China	2004–2006	Case-Control	Anti-HCV+	ICC	312 (2.9%)	438 (1.4%)	0.93 (0.3–3.1)	Age, sex, date of admission

^ Diagnostic code; HCV = Hepatitis C virus; CC = cholangiocarcinoma; NS = not specified; ICC = intrahepatic cholangiocarcinoma; ECC = extrahepatic cholangiocarcinoma; CI = confidence interval

Table 5

Cirrhosis as a Potential Risk factor for Cholangiocarcinoma

First author	Country	Study dates	Study design	Risk factor	CC type	Cases (% with risk factor)	Controls (case-control study)/individuals at risk (cohort study)	Risk estimate (95% CI)	Selected adjusted variables
Sorensen ⁵²	Denmark	1977–1993	Cohort	Cirrhosis	NS	21	11,605	10.0 (6.2–15.2)	
Yamamoto ⁵¹	Japan	1991–2002	Case-control	Cirrhosis	ICC	50 (10%)	205 (1%)	5.03 (.045–56.82)	Age, sex
Shalib ⁴⁷	US	1993–1999	Case-control	^ Cirrhosis	ICC	625 (8.5%)	90,834 (0.4%)	27.2 (19.9–37.1)	Age, sex, race, geographic location
Welzel ²⁸	US	1993–1999	Case-Control	^ Cirrhosis	ICC	535 (3.2%)	102,782 (0.3%)	10.0 (6.1–16.4)	Age, sex, race, geographic location
					ECC	549 (1.8%)	102,782 (0.3%)	5.4 (2.9–10.2)	
Lee ²⁷	Korea	2000–2004	Case-control	Cirrhosis	ICC	622 (7.8%)	2,488 (0.4%)	13.6 (6.5–28.5)	Age, sex

^ Diagnostic code; CC = cholangiocarcinoma; NS = not specified; ICC = intrahepatic cholangiocarcinoma; ECC = extrahepatic cholangiocarcinoma; CI = confidence interval

Table 6

Obesity and Diabetes as Potential Risk factors for Cholangiocarcinoma

First author	Country	Study dates	Study design	Risk factor	CC Type	Cases (% with risk factor)	Controls (% with risk factor)	Risk estimate (95% CI)	Selected adjusted variables
Welzel ⁴⁸	Denmark	1978–1991	Case-Control	[^] Diabetes	ICC	764 (1.96%)	3,056 (1.41%)	1.43 (0.8–2.6)	Age, sex
				[^] Obesity	ICC	764 (0.79%)	3,056 (0.39%)	2.05 (0.7–5.6)	
Grainge ⁵⁶	United Kingdom	1987–2002	Case-Control	[^] Diabetes	NS	372 (9.4%)	5,760 (5.9%)	1.48 (1.0–2.2)	Age, sex, practice group
				Obesity (BMI ≥30)	NS	372 (19.6%)	5,760 (15.7%)	1.52 (1.0–2.2)	
Yamamoto ⁵¹	Japan	1991–2002	Case-control	Diabetes	ICC	50 (22%)	205 (12%)	1.95 (0.6–5.8)	Age, sex
Shaib ⁵³	US	1992–2002	Case-control	Diabetes	ICC	83 (14.5%)	236 (8.5%)	Not calculated	Age, sex, race
				Diabetes	ECC	163 (11.7%)	236 (8.5%)	Not calculated	
Shaib ⁴⁷	US	1993–1999	Case-control	[^] Diabetes	ICC	625 (26.4%)	90,834 (15.6%)	2.0 (1.6–2.4)	Age, sex, race, geographic location
Welzel ²⁸	US	1993–1999	Case-Control	[^] Diabetes	ICC	535 (33.1%)	102,782 (22.1%)	1.8 (1.5–2.1)	Age, sex, race, geographic location
				[^] Diabetes	ECC	549 (30.1%)	102,782 (22.1%)	1.5 (1.3–1.8)	
				[^] Obesity	ICC	535 (4.3%)	102,782 (3.1%)	1.7 (1.1–2.6)	
				[^] Obesity	ECC	549 (2.9%)	102,782 (3.1%)	1.1 (0.7–1.8)	
Lee ²⁷	Korea	2000–2004	Case-control	Diabetes	ICC	622 (15.4%)	2,488 (5.6%)	3.2 (2.3–4.3)	Age, sex
Zhou ⁴¹	China	2004–2006	Case-Control	Diabetes	ICC	312 (4.2%)	438 (2.5%)	1.5 (0.6–3.8)	Age, sex, date of admission

[^] Diagnostic code; CC = cholangiocarcinoma; ICC = intrahepatic cholangiocarcinoma; ECC = extrahepatic cholangiocarcinoma; CI = confidence interval

Table 7

Alcohol Drinking and Tobacco Smoking as Potential Risk factors for Cholangiocarcinoma

First author	Country	Study dates	Study design	Risk factor	CC Type	Cases (% with risk factor)	Controls (% with risk factor)	Risk estimate (95% CI)	Selected adjusted variables
Sorensen ⁵²	Denmark	1977–1993	Cohort	Alcoholic cirrhosis	NS	17	11,605	15.3 (8.9–24.5)	
Grainge ⁵⁶	United Kingdom	1987–2002	Case-Control	Smoking (current exposure)	NS	372 (27.5%)	5,760 (20.9%)	1.38 (1.0–1.9)	Age, sex, practice group
				^ Alcohol (problem drinker)	NS	372 (0.3%)	5,760 (0.7%)	Not calculated	
Shin ¹⁷	Korea	1990–1993	Case-control	Heavy Smoking (>1 pack/day, >10 years)	NS	41 (36.6%)	406 (46.8%)	0.8 (0.2–2.5)	Age, sex, socioeconomic status
				Heavy Alcohol (>80g/day, >10 years)	NS	41 (22%)	406 (11.1%)	4.6 (1.4–15.2)	
Yamamoto ⁵¹	Japan	1991–2002	Case-control	Smoking (Any previous exposure)	ICC	50 (34%)	205 (44%)	Not calculated	Age, sex
				Heavy Alcohol (>5 go sake/day, >10 years)	ICC	50 (2%)	205 (5%)	0.97 (0.5–1.9)	
Shaib ⁵³	US	1992–2002	Case-control	Smoking (>25 pack years)	ICC	83 (24.1%)	236 (15.7%)	Not calculated	Age, sex, race
				Smoking (>25 pack years)	ECC	163 (20.9%)	236 (15.7%)	Not calculated	
				Heavy Alcohol (>80g/day)	ICC	83 (21.7%)	236 (3.8%)	5.9 (2.1–17.4)	
				Heavy Alcohol (>80g/day)	ECC	163 (17.8%)	236 (3.8%)	3.6 (1.5–9.4)	
				Mild/Moderate Alcohol (80g/day)	ICC	83 (33.7%)	236 (48.3%)	Not calculated	
				Mild/Moderate Alcohol (80g/day)	ECC	163 (26.9%)	236 (48.3%)	0.5 (0.3–0.8)	
Shaib ⁴⁷	US	1993–1999	Case-control	^ Smoking	ICC	625 (3.8%)	90,834 (2.1%)	1.8 (1.2–2.70)	Age, sex, race, geographic location
				^ Alcoholic liver disease	ICC	625 (2.2%)	90,834 (0.3%)	7.4 (4.3–12.8)	
Welzel ²⁸	US	1993–1999	Case-Control	^ Smoking	ICC	535 (2.2%)	102,782 (1.2%)	1.8 (1.0–3.2)	Age, sex, race, geographic location
				^ Smoking	ECC	549 (2.2%)	102,782 (1.2%)	1.7 (1.0–3.0)	
				^ Alcoholic liver disease	ICC	535(0.9%)	102,782 (0.3%)	3.1 (1.3–7.5)	
				^ Alcoholic liver disease	ECC	549 (1.5%)	102,782 (0.3%)	4.5 (2.2–9.1)	
Donato ⁴²	Italy	1995–2000	Case control	Heavy Alcohol (>80g/day)	ICC	26 (23.1%)	824 (33%)	0.4 (0.2–1.6)	Age, sex, residence
Lee ²⁷	Korea	2000–2004	Case-control	Smoking (Any prior exposure)	ICC	622 (47.1%) (45.6%)	2,488	Not calculated	Age, sex

First author	Country	Study dates	Study design	Risk factor	CC Type	Cases (% with risk factor)	Controls (% with risk factor)	Risk estimate (95% CI)	Selected adjusted variables
Zhou ⁴¹	China	2004–2006	Case-Control	Heavy Alcohol (>80g/day)	ICC	622 (18%)	2,488 (3.1%)	6.6 (4.8–9.2)	
				Smoking (≥ 4 day/week, ≥ 6 months)	ICC	312 (13.8%)	438 (15.3%)	1.23 (0.7–2.2)	Age, sex, date of admission
				Alcohol (≥ 1 drink/week, ≥ 6 months)	ICC	312 (12.5%)	438 (9.4%)	0.80 (0.5–1.3)	

⁴¹ Diagnostic code; CC = cholangiocarcinoma; NS = not specified; ICC = intrahepatic cholangiocarcinoma; ECC = extrahepatic cholangiocarcinoma; CI = confidence interval

Table 8

Genetic polymorphisms as Potential Risk factors of Cholangiocarcinoma

First author	Country	Polymorphism	CC Type	Cases	Controls	Risk estimate (95% CI)	Selected adjusted variables
KO ⁴⁹	Korea	MTHFR 677CC + TSER 2R+	NS	47	204	5.38 (1.2–23.6)	
Marahatta ⁶⁰	Thailand	GSTO1* A140D	NS	30	98	8.5 (2.1–37.8)	Sex, race
Hoblinger ⁵⁷	Germany	MRP2/ABCC2 variant c.3972C>T	ICC/ECC	60	73	1.83 (1.1–3.1)	
Melum ⁶¹	Scandinavia	NKG2D rs11053781 + PSC	NS	49	368	2.08 (1.3–3.3)	Sex
		NKG2D rs2617167 + PSC	NS	49	368	2.32 (1.5–3.7)	
		MICA 5.1 + PSC	NS	49	368	0.43 (0.2–0.9)	
Prawan ⁶²	Thailand	# CYP1A2*1A*1A	NS	216	233	0.28 (0.1–0.9)	Age, sex
		NAT2* 13,*6B,*7A	NS	216	233	0.26–0.38	
Huang ⁵⁸	China	XRCC1 194W	NS	127	786	1.9 (1.1–3.5)	Age, sex, hospital
		XRCC1 R280H	NS	127	786	0.5 (0.3–0.9)	
Sakoda ⁶³	China	PTGS2 Ex 10 +837 C	NS	127	786	1.8 (1.2–2.7)	Age, sex, hospital

In males

MTHFR = 5,10-Methylenetetrahydrofolate reductase is a key enzyme in folate metabolism and provides methyl groups for DNA methylation

TS = Thymidylate synthase is a rate-limiting enzyme in the synthesis of dTMP and DNA repair

GST = Glutathione S-transferases are a family of detoxification enzymes

MRP2/ABCC2 = Multidrug resistance-associated protein 2 is one of the ATP-binding cassette transporters that is involved in biliary clearance of endogenous and exogenous toxic compounds

PSC = Primary sclerosing cholangitis

NKG2D = Natural killer cell receptor is involved in activation of natural killer (NK) cells which are important for tumor surveillance

MICA = Major histocompatibility complex class I chain-related molecule A is a ligand to NKG2D

CYP1A2 = member of cytochrome P450 involved in activation of carcinogens

NAT = N-acetyltransferases are involved in metabolism and detoxification of amines

BER = Base excision repair corrects DNA damage caused by oxidative stress which encompass the x-ray repair cross complementing group 1 (XRCC1)

PTGS2 = Prostaglandin-endoperoxide synthase 2 is induced by inflammation

CC= Cholangiocarcinoma

NS= Not specified

ICC= Intrahepatic cholangiocarcinoma
ECC= Extrahepatic cholangiocarcinoma
CI= Confidence interval